10q10k10q10k.net
Bone Biologics Corp

Bone Biologics CorpBBLGEarnings & Financial Report

Nasdaq · Health Care · Orthopedic, Prosthetic & Surgical Appliances & Supplies

Bone Biologics Corp is a clinical-stage biotechnology firm focused on developing orthobiologic products to boost bone regeneration and healing for orthopedic surgery patients, including spinal fusion recipients. It mainly operates in the U.S. healthcare market, targeting orthopedic care and regenerative medicine segments.

Q1 2024Q4 2023Q3 2023Q2 2023Q1 2023

BBLG Q1 FY2024 Key Financial Metrics

Revenue

$255

Gross Profit

N/A

Operating Profit

$-903.5K

Net Profit

$-866.0K

Gross Margin

N/A

Operating Margin

-354327.8%

Net Margin

-339596.1%

YoY Growth

-54.1%

EPS

$-1.31

Bone Biologics Corp Q1 FY2024 Financial Summary

Bone Biologics Corp reported revenue of $255 (down 54.1% YoY) for Q1 FY2024, with a net profit of $-866.0K (up 76.7% YoY) (-339596.1% margin).

Key Financial Metrics

Total Revenue$255
Net Profit$-866.0K
Gross MarginN/A
Operating Margin-354327.8%
Report PeriodQ1 FY2024

Bone Biologics Corp Annual Revenue by Year

Bone Biologics Corp annual revenue history includes year-by-year totals (for example, 2023 revenue was $1.9K).

YearAnnual Revenue
2023$1.9Kvs 2022 →

Bone Biologics Corp Quarterly Revenue & Net Profit History

Bone Biologics Corp results over the last 5 reported quarters, including revenue, net profit and year-over-year growth.

QuarterRevenueRevenue YoYNet ProfitNet Margin
Q1 FY2024$255-54.1%$-866.0K-339596.1%
Q4 FY2023$348—$-1.5M-445369.3%
Q3 FY2023$536—$-1.9M-358154.7%
Q2 FY2023$428—$-1.8M-413373.4%
Q1 FY2023$556—$-3.7M-667248.0%

Income Statement

Q1 2023Q2 2023Q3 2023Q4 2023Q1 2024
Revenue$556$428$536$348$255
YoY GrowthN/AN/AN/AN/A-54.1%

Balance Sheet

Q1 2023Q2 2023Q3 2023Q4 2023Q1 2024
Assets$6.8M$7.6M$5.0M$3.7M$3.8M
Liabilities$4.0M$1.9M$1.2M$831402$164626
Equity$2.8M$5.7M$3.8M$2.9M$3.7M

Cash Flow

Q1 2023Q2 2023Q3 2023Q4 2023Q1 2024
Operating CF$-1.3M$-3.6M$-2.6M$-2.0M$-1.3M